Triptan nonresponders: Do they exist and who are they?

Cephalalgia

Volumn 33, Issue 11, 2013, Pages 891-896

  Viana, Michele ^a   Genazzani, Armando A ^b   Terrazzino, Salvatore ^b   Nappi, Giuseppe ^a   Goadsby, Peter J ^c  

^a C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

migraine; nonresponder; population; predictor; responder; Triptan

Indexed keywords

ALMOTRIPTAN; NAPROXEN; NARATRIPTAN; SUMATRIPTAN; TRIPTAN DERIVATIVE;

ANALGESIA; CLINICAL PRACTICE; CLINICAL PROTOCOL; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; HUMAN; MIGRAINE; MIGRAINE WITH AURA; PATIENT COMPLIANCE; PATIENT SATISFACTION; PHYSICIAN; PLACEBO EFFECT; REVIEW; SELF CONCEPT; STOMACH PARESIS; STUDY DESIGN; TREATMENT RESPONSE;

MIGRAINE; NONRESPONDER; POPULATION; PREDICTOR; RESPONDER; TRIPTAN;

ANALGESICS; DRUG RESISTANCE; HUMANS; MIGRAINE DISORDERS; TRYPTAMINES;

EID: 84879979228     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1177/0333102413480756     Document Type: Review

References (21)

1. Ferrari MD, Goadsby PJ, Roon KI, et al. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: Detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002 ; 22: 633-658
2. Buzzi MG. Pathways to the best fit of triptans for migraine patients. Cephalalgia. 2008 ; 28: 21-27
3. Cady RK, Freitag FG, Mathew NT, et al. Allodynia-associated symptoms, pain intensity and time to treatment: Predicting treatment response in acute migraine intervention. Headache. 2009 ; 49: 350-363
4. Barbanti P, Fabbrini G, Vanacore N, et al. Sumatriptan in migraine with unilateral cranial autonomic symptoms: An open study. Headache. 2003 ; 43: 400-403
5. Sarchielli P, Pini LA, Zanchin G, et al. Clinical-biochemical correlates of migraine attacks in rizatriptan responders and non-responders. Cephalalgia. 2006 ; 26: 257-265
6. Diener HC, Limmroth V. Advances in pharmacological treatment of migraine. Expert Opin Investig Drugs. 2001 ; 10: 1831-1845
7. Ho TW, Rodgers A, Bigal ME. Impact of recent prior opioid use on rizatriptan efficacy. A post hoc pooled analysis. Headache. 2009 ; 49: 395-403
8. Dodick DW. Triptan nonresponder studies: Implications for clinical practice. Headache. 2005 ; 45: 156-162
9. Lainez MJ. Almotriptan: Meeting today's needs in acute migraine treatment. Expert Rev Neurother. 2007 ; 7: 1659-1673
10. Dahlof CG. Infrequent or non-response to oral sumatriptan does not predict response to other triptans - review of four trials. Cephalalgia. 2006 ; 26: 98-106
11. Terrazzino S, Viana M, Floriddia E, et al. The serotonin transporter gene polymorphism STin2 VNTR confers an increased risk of inconsistent response to triptans in migraine patients. Eur J Pharmacol. 2010 ; 641: 82-87
12. Asuni C, Cherchi A, Congiu D, et al. Association study between clinical response to rizatriptan and some candidate genes. J Headache Pain. 2007 ; 8: 185-189
13. Stark S, Spierings EL, McNeal S, et al. Naratriptan efficacy in migraineurs who respond poorly to oral sumatriptan. Headache. 2000 ; 40: 513-520
14. Farkkila M, Olesen J, Dahlof C, et al. Eletriptan for the treatment of migraine in patients with previous poor response or tolerance to oral sumatriptan. Cephalalgia. 2003 ; 23: 463-471
15. Mathew NT, Kailasam J, Gentry P, et al. Treatment of nonresponders to oral sumatriptan with zolmitriptan and rizatriptan: A comparative open trial. Headache. 2000 ; 40: 464-465
16. Diener HC, Gendolla A, Gebert I, et al. Almotriptan in migraine patients who respond poorly to oral sumatriptan: A double-blind, randomized trial. Headache. 2005 ; 45: 874-882
17. Goldstein J, Tiseo PT, Albert KS, et al. Eletriptan in migraine patients reporting unsatisfactory response to rizatriptan. Headache. 2006 ; 46: 1142-1150
18. Mathew NT, Landy S, Stark S, et al. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life. Headache. 2009 ; 49: 971-982
19. Lipton RB, Hamelsky SW, Dayno JM. What do patients with migraine want from acute migraine treatment?. Headache. 2002 ; 42: 3-9
20. Tfelt-Hansen P, Pascual J, Ramadan N, et al. Guidelines for controlled trials of drugs in migraine: Third edition. A guide for investigators. Cephalalgia. 2012 ; 32: 6-38
21. Goadsby PJ, Zanchin G, Geraud G, et al. Early vs. non-early intervention in acute migraine-'Act when Mild (AwM)'. A double-blind, placebo-controlled trial of almotriptan. Cephalalgia. 2008 ; 28: 383-391